Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation

Blood

Volumn 100, Issue 7, 2002, Pages 2530-2536

  Walton, Kimberly J ^a   Duncan, Joanne M ^a   Deschamps, Paula ^a   Shaughnessy, Stephen G ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; DNA; GLYCOPROTEIN GP 130; HEPARIN; INTERLEUKIN 11; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN DERIVATIVE; SERINE; STAT3 PROTEIN; TYROSINE;

ANIMAL CELL; ARTICLE; BONE ATROPHY; BONE MARROW CELL; CALVARIA; COCULTURE; CONTROLLED STUDY; DNA PROTEIN COMPLEX; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOSTIMULATION; LONG TERM CARE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; PHOSPHORYLATION; PRIORITY JOURNAL; TRANSACTIVATION;

EID: 0036785334     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.7.2530     Document Type: Article

References (50)

1. Avioli LV. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol. 1975;52:375-387.
2. Griffith CC, Nichols G, Asher JD, Flanagan B. Heparin osteoporosis. JAMA. 1965;193:85-88.
3. Jaffe MD, Willis PW. Multiple fractures associated with long term sodium heparin therapy. JAMA. 1965;193:152-154.
4. Miller WE, DeWolfe VG. Osteoporosis resulting from heparin therapy. Cleveland Clin Q. 1966;33:31-34.
5. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. 1994;170:1315-1320.
6. Squires JW, Pinch LWC. Heparin-induced spinal fractures. JAMA. 1979;241:2417-2418.
7. Murphy MS, John PR, Mayer AD, Buckels JAC, Kelly DA. Heparin therapy and bone fractures. Lancet. 1992;340:1098.
8. Monreal M, Olive A, Lafoz E, Del Rio L. Heparins, coumarin, and bone density. Lancet. 1991;338:706.
9. Rupp WM, McCarthy HB, Rohde TD, et al. Risk of osteoporosis in patients treated with long-term intravenous heparin therapy. Curr Surg. 1982;39:419-422.
10. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol. 1994;170:862-869.
11. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11.
12. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168:1265-1270.
13. Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 1996;88:1314-1320.
14. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats. Blood. 1997;89:3236-3242.
15. Elias JA, Tang W, Horowitz MC. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology. 1995;136:489-498.
16. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine. 2000;12:613-621.
17. Romas E, Udagawa N, Zhou H, et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996;183:2581-2591.
18. Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516-1524.
19. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell. 1994;76:253-262.
20. Stahl N, Boulton TG, Farruggella T, et al. Association and activation of Jak-Tyk kinases by CNTFLIF-OSM-IL-6 β receptor components. Science. 1994;263:92-95.
21. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6 type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297-314.
22. Zhong Z, Wen Z, Darnell J Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95-98.
23. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597-3602.
24. Lütticken C, Wegenka UM, Yuan J, et al. Association of transcription factor APRF and protein kinase Jakl with the interleukin-6 signal transducer gp130. Science. 1994;263:89-92.
25. Narazaki M, Witthuhn BA, Yoshida K, et al. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A. 1994;91:2285-2289.
26. Wen Z, Zhong Z. Darnell JE Jr. Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250.
27. Schuringa J, Jonk LJC, Dokter WHA, Vellenga E, Kruijer W. Interleukin-6-induced STAT3 transactivation and Ser 727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J. 2000;347:89-96.
28. Zhang X, Blenis J, Li H, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995;267:1990-1994.
29. Ng J, Cantrell D. STAT3 is a serine kinase target in T Lymphocytes: interleukin 2 and T cell antigen receptor signals converge upon serine 727. J Biol Chem. 1997;272:24542-24549.
30. Chung J, Uchida E, Grammar TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 1997;17:6508-6516.
31. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem. 1999;274:19301-19308.
32. O'Brien CA, Manolagas SC. Isolation and characterization of the human gp130 promoter; regulation by STATS. J Biol Chem. 1997;272:15003-15010.
33. O'Brien CA, Lin SC, Bellido T, Manolagas SC. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6 type cytokines. J Cell Biochem. 2000;79:532-541.
34. Bruno E, Briddell RA, Cooper RJ, Hoffman R. Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol. 1991;19:378-381.
35. Neben TY, Loebelenz J, Hayes L, et al. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood. 1993;81:901-908.
36. Weich NS, Wang A, Fitzgerald M, et al. Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood. 1997;90:3893-3902.
37. Quesniaux VF, Clark SC, Turner K, Fagg B. Interleukin-11 stimulates multiple phases of erythropoiesis in vitro. Blood. 1992;80:1218-1223.
38. Rodriguez MH, Arnaud S, Blanchet JP. IL-11 directly stimulates murine and human erythroid burst formation in semisolid cultures. Exp Hematol. 1995;23:545-550.
39. de Haan G, Dontje B, Engel C, Loeffler M, Nijhof W. In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis. Br J Haematol. 1995;90:783-790.
40. Galmiche MC, Vogel CA, Delaloye AB, et al. Combined effects of interleukin-3 and interleukin-11 on hematopoiesis in irradiated mice. Exp Hematol. 1996;24:1298-1306.
41. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol. 1999;65:715-724.
42. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
43. Lacey D, Timms E, Tan H, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
44. Fuller K, Wong B, Fox S, Choi Y, Chambers T. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188:997-1001.
45. Kong Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
46. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol. 1999;163:4583-4589.
47. Schooltink H, Schmitz-Van de Leur H, Heinrich PC, Rose-John S. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett. 1992;297:263-265.
48. Hurley MM, Kessler M, Gronowicz G, Raisz LG. The interaction of heparin and basic fibroblast growth factor on collagen synthesis in 21-day fetal rat calvariae. Endocrinology. 1992;130:2675-2682.
49. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278:1803-1805.
50. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene. 2000;19:2638-2644.